Sanofi (SNY) Expected to Announce Earnings on Thursday

Sanofi (NASDAQ:SNY) will likely be releasing its earnings data before the market opens on Thursday, January 30th. Analysts expect Sanofi to post earnings of $0.76 per share and revenue of $10,981,627.75 billion for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the business posted $2.55 earnings per share. The business’s revenue was up 12.3% compared to the same quarter last year. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $53.34 on Tuesday. The business’s fifty day moving average price is $48.80 and its two-hundred day moving average price is $52.21. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a market capitalization of $135.37 billion, a price-to-earnings ratio of 27.21, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.